Author:
Nguyen Phuong Quoc Mai,Wang Ming,Ann Maria Nelisha,Li Adelicia Yongling,Tan Hsih Yin,Xiong Gordon Minru,Tan Meng-Kwang Marcus,Bhagat Ali Asgar S.,Ong Catherine W. M.,Lim Chwee Teck
Abstract
AbstractEffective containment of the COVID-19 pandemic requires rapid and accurate detection of the pathogen. Polymerase chain reaction (PCR) remains the gold standard for COVID-19 confirmation. In this article, we report the performance of a cost-effective modular microfluidic reverse transcription (RT)-PCR and RT-loop mediated isothermal amplification (RT-LAMP) platform, Epidax®, for the point-of-care testing and confirmation of SARS-CoV-2. This platform is versatile and can be reconfigured either for screening using endpoint RT-PCR or RT-LAMP tests or for confirmatory tests using real-time RT-PCR. Epidax® is highly sensitive and detects as little as 1 RNA copy per µL for real-time and endpoint RT-PCR, while using only half of the reagents. We achieved comparable results with those of a commercial platform when detecting SARS-CoV-2 viruses from 81 clinical RNA extracts. Epidax® can also detect SARS-CoV-2 from 44 nasopharyngeal samples without RNA extraction by using a direct RT-PCR assay, which shortens the sample-to-answer time to an hour with minimal user steps. Furthermore, we validated the technology using an RT-LAMP assay on 54 clinical RNA extracts. Overall, our platform provides a sensitive, cost-effective, and accurate diagnostic solution for low-resource settings.
Funder
National University of Singapore
Publisher
Springer Science and Business Media LLC
Subject
Electrical and Electronic Engineering,Industrial and Manufacturing Engineering,Condensed Matter Physics,Materials Science (miscellaneous),Atomic and Molecular Physics, and Optics
Reference44 articles.
1. Carter, L. J. et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent. Sci. 6, 591–605 (2020).
2. Vandenberg, O., Martiny, D., Rochas, O., van Belkum, A. & Kozlakidis, Z. Considerations for diagnostic COVID-19 tests. Nat. Rev. Microbiol. https://doi.org/10.1038/s41579-020-00461-z (2020).
3. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. New Engl. J. Med. 382, 727–733 (2020).
4. Cepheid. US Food and Drug Administration, Coronavirus (COVID-19) Update: FDA Issues First Emergency Use Authorization For Point Of Care Diagnostic. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-first-emergency-use-authorization-point-care-diagnostic. Accessed 14 Nov 2021. (2020).
5. Roche. Roche’s cobas SARS-CoV-2 Test To Detect Novel Coronavirus Receives FDA Emergency Use Authorization and is Available in Markets Accepting the CE Mark. https://diagnostics.roche.com/global/en/news-listing/2020/roche-receives-fda-emergency-use-authorization-for-cobas-sars-co.html. Accessed 14 Nov 2021. (2020).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献